Biopsy Devices Market Forecast 2019 with CareFusion, Hologic, Inc. , Mammotome, a Division of Devicor Medical Pro

The Biopsy Devices Market set to exceed is expected to witness growth of over 6.5% CAGR from 2018 to 2024 new research report by Global Market Insights.
Rising prevalence of cancer and infections will stimulate biopsy devices market growth over the forthcoming period. Infectious diseases are rapidly emerging worldwide due to changing environmental conditions and rising population.
According to World Health Organization, 50,000 people worldwide die from infectious diseases. In addition, infections with new and unknown causative agents have increased tremendously during recent years. Biopsy is thus a crucial tool for histopathological examination of tissue. Rising number of kidney disorders, infections and rising cancer incidence should increase the market size over the upcoming period.

Growing awareness regarding breast cancer treatment and diagnosis will support increase in biopsy devices market size in upcoming years. Several countries hold campaigns and programs for early diagnosis of breast cancer. In U.S., early detection camps are set-up in rural areas wherein diagnosis of cancer is done through biopsy of suspicious lesions and oral examinations, every four months. Such initiatives will accelerate the adoption rate of biopsy devices, thereby positively impacting biopsy devices business growth in foreseeable future.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/731

Technological advancements in biopsy devices will lead to faster adoption of biopsy devices in coming years. Conventional biopsy for prostate biopsy without using imaging guidance technology render negative tests or misses tumor in maximum cases. Thus, evolution of technologies such as MRI/ultrasound for accurate and reliable diagnosis of lesions is leading to faster adoption of biopsy procedures. Koelis developed Organ-Based Tracking (OBT) Revolution that works in tandem with elastic fusion technology, thus maximizing accuracy of the procedure. Such innovations allowing better and improved diagnosis of abnormalities will drive global biopsy devices industry over the upcoming period.

Biopsy guidance systems segment accounted for largest revenue size of USD 855.4 million in 2017. As per data from Journal of Clinical Pathways, during the recent years, more than half biopsies were guided by computed tomography systems and other procedures such as ultrasound/fluoroscopy. Guidance systems offer high-definition images of the abnormalities/tissue, are minimally invasive as well as cost-effective. In addition, several companies are concentrating on R&D to innovate newer imaging technologies that should impel biopsy guidance systems segment growth over the forecast timeframe.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
 CareFusion
 Hologic, Inc. ,
 Mammotome, a Division of Devicor Medical Pro

Needle based biopsy guns segment is forecasted to grow at 7.2% CAGR during the forecast period. Fine needle aspiration (FNA) is minimally invasive procedure and requires extraction of only fewer cells for diagnosis. Needle-based biopsy is reliable and offers accurate diagnosis of the abnormalities/disease. Above benefits of needle-based biopsy guns coupled with increasing demand for minimally invasive procedures will spur segmental growth.

Hospitals end-user segment held the largest market share of 69.2% in 2017 and will dominate the market throughout the forecast timeframe. Biopsy accounts for the most frequently performed procedures in hospital settings. As per Journal of Clinical Pathways, image-guided percutaneous liver biopsy (PLB) is rising at a fast pace in patients affected by hepatocellular carcinoma. With escalating epidemiology of infectious diseases along with rising healthcare spending, hospitals end-user segment is forecasted to grow robustly in coming years.

Browse Full Report Details @ https://www.gminsights.com/industry-analysis/biopsy-devices-market

Ambulatory surgical centers (ASCs) end-user segment will record high CAGR at 9.0% over the projected period. ASCs are witnessing rapid demand for procedures due to its speciality, faster procedural time as well as shorter stays. Availability of reimbursement for biopsy devices coupled with procedural reimbursement will further serve as high impacting factor, favouring significant segmental growth in future.

U.S. market accounted for highest revenue share of 81.0% North America biopsy devices market in 2017. Expanding cases of cancer coupled with growing awareness of cancer diagnosis and treatment in the country is estimated to offer accelerating demand for biopsy devices in future. For instance, October is considered as the breast cancer awareness month, wherein rallies, breast-cancer awareness campaigns and events are held. Furthermore, sophisticated healthcare infrastructure and growing prevalence of infections will positively impact U.S. biopsy devices industry growth over the projected timeframe.

France market will grow at remarkable pace of 6.2% throughout the forecast period. Growing incidence of cancer will act as a high impacting factor for France market growth. According to Cancer Organisation Soutien, 385,000 new cases of cancer were diagnosed in France in the year 2015 and incidence of cancer is increasing considerably. In addition, breast cancer is the leading cause of mortality in women. With such accelerating pervasiveness of cancer, France biopsy devices will foresee lucrative growth over forthcoming years.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/731

Biopsy was formerly performed in Russia by M. M. Rudnev in 1875 followed by first breast biopsy performed during 1850s by Skey, Sr. James Paget, John Eric Erichsen and Prtichard. The evolution of first biopsy needle can be dated back to early 1930s. During 1981, analog mammography system Mammomat B by Siemens Healthineers offered biopsy paddle for localization of needle under mammography supervision.

Subsequent developments in other biopsy types such as prostate biopsy, renal biopsy and infections through technological advancements including imaging-guided biopsy marked robust industrial growth. Additionally, renal biopsy will foresee lucrative growth opportunity as a result of rapid developments in imaging technologies including Magnetic particle imaging (MPI) modality that allows localization of localization of super paramagnetic nanoparticles at high resolution. Such advancements are forecasted to spur biopsy devices industrial growth in foreseeable future.

About Global Market Insights:
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com
Blog: http://solutionrocket.com

This release was published on openPR.